Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
RXi Pharmaceuticals, Corp.
Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of RXI-109 when administered by intravitreal injection. Evaluate the clinical activity of single and multiple doses of RXI-109 when administered by intravitreal injection. Study participation is intended to be seven months from time of initial treatment with RXI-109.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects presenting with advanced NVAMD in the study eye with BCVA ≤20/100 potentially due to subretinal fibrosis involving the fovea
BCVA ≥20/800 in the contralateral eye and better than the study eye
≥50 years of age
Subfoveal choroidal neovascularization (CNV) of any type
You may not be if
Presence of other causes of CNV including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis
Evidence of inflammation (Grade 1 or higher) in the anterior or posterior chamber
Clareo Health | Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
